{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T04:19:47Z","timestamp":1783138787780,"version":"3.54.6"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s10072-023-06608-z","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T13:02:42Z","timestamp":1674478962000},"page":"2121-2129","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0956-3304","authenticated-orcid":false,"given":"Cavit","family":"Boz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serkan","family":"Ozakbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Terzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Karabudak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serhan","family":"Sevim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Recai","family":"Turkoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysun","family":"Soysal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belgin Petek","family":"Balc\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00fcsn\u00fc","family":"Efendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6mer Faruk","family":"Turan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur","family":"Y\u00fcceyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Fatih","family":"Yetkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serap Zengin","family":"Karahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meltem","family":"Demirk\u0131ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibel","family":"Guler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadriye","family":"Agan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nefati","family":"K\u0131yl\u0131o\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cavid","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asli","family":"Tuncer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mesrure","family":"K\u00f6seo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,23]]},"reference":[{"issue":"14","key":"6608_CR1","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","volume":"365","author":"P O'Connor","year":"2011","unstructured":"O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP et al (2011) Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 365(14):1293\u20131303","journal-title":"N Engl J Med."},{"issue":"5","key":"6608_CR2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P et al (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 362(5):387\u2013401","journal-title":"N Engl J Med."},{"issue":"3","key":"6608_CR3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B et al (2017) Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 376(3):221\u2013234","journal-title":"N Engl J Med."},{"issue":"9","key":"6608_CR4","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 354(9):899\u2013910","journal-title":"N Engl J Med."},{"issue":"10","key":"6608_CR5","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1177\/1352458516650736","volume":"22","author":"D Baroncini","year":"2016","unstructured":"Baroncini D, Ghezzi A, Annovazzi PO, Colombo B, Martinelli V, Minonzio G et al (2016) Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies. Mult Scler. 22(10):1315\u20131326","journal-title":"Mult Scler."},{"issue":"1","key":"6608_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1177\/1352458515579216","volume":"22","author":"T Frisell","year":"2016","unstructured":"Frisell T, Forsberg L, Nordin N, Kiesel C, Alfredsson L, Askling J et al (2016) Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis. Mult Scler. 22(1):85\u201393","journal-title":"Mult Scler."},{"issue":"3","key":"6608_CR7","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/ana.24339","volume":"77","author":"T Kalincik","year":"2015","unstructured":"Kalincik T, Horakova D, Spelman T, Jokubaitis V, Trojano M, Lugaresi A et al (2015) Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. Ann Neurol. 77(3):425\u2013435","journal-title":"Ann Neurol."},{"issue":"2","key":"6608_CR8","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1177\/1352458516643393","volume":"23","author":"N Koch-Henriksen","year":"2017","unstructured":"Koch-Henriksen N, Magyari M, Sellebjerg F, Soelberg SP (2017) A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod. Mult Scler. 23(2):234\u2013241","journal-title":"Mult Scler."},{"issue":"6","key":"6608_CR9","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1177\/1352458518768433","volume":"24","author":"J Lorscheider","year":"2018","unstructured":"Lorscheider J, Benkert P, Lienert C, H\u00e4nni P, Derfuss T, Kuhle J et al (2018) Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis. Mult Scler. 24(6):777\u2013785","journal-title":"Mult Scler."},{"issue":"11","key":"6608_CR10","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s40263-021-00860-7","volume":"35","author":"S Sharmin","year":"2021","unstructured":"Sharmin S, Lefort M, Andersen JB, Leray E, Horakova D, Havrdova EK et al (2021) Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis: a subgroup analysis from three international cohorts. CNS Drugs. 35(11):1217\u20131232","journal-title":"CNS Drugs."},{"key":"6608_CR11","doi-asserted-by":"publisher","unstructured":"Rollot F, Couturier J, Casey R, Wiertlewski S, Debouverie M, Pelletier J et al (2022) Comparative effectiveness of natalizumab versus anti-CD20 in highly active relapsing-remitting multiple sclerosis after fingolimod withdrawal.\u00a0Neurother 19(2):476\u2013490. https:\/\/doi.org\/10.1007\/s13311-022-01202-1","DOI":"10.1007\/s13311-022-01202-1"},{"issue":"5","key":"6608_CR12","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1177\/1352458516662728","volume":"23","author":"T Kalincik","year":"2017","unstructured":"Kalincik T, Kuhle J, Pucci E, Rojas JI, Tsolaki M, Sirbu CA et al (2017) Data quality evaluation for observational multiple sclerosis registries. Mult Scler. 23(5):647\u2013655","journal-title":"Mult Scler."},{"issue":"Suppl 3","key":"6608_CR13","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1212\/WNL.0b013e3181dbb51c","volume":"74","author":"E Havrdova","year":"2010","unstructured":"Havrdova E, Galetta S, Stefoski D, Comi G (2010) Freedom from disease activity in multiple sclerosis. Neurology. 74(Suppl 3):S3\u2013S7","journal-title":"Neurology."},{"issue":"Pt 11","key":"6608_CR14","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1093\/brain\/awv258","volume":"138","author":"T Kalincik","year":"2015","unstructured":"Kalincik T, Cutter G, Spelman T, Jokubaitis V, Havrdova E, Horakova D et al (2015) Defining reliable disability outcomes in multiple sclerosis. Brain. 138(Pt 11):3287\u20133298","journal-title":"Brain."},{"key":"6608_CR15","volume-title":"R: a language and environment for statistical computing","author":"Team RC","year":"2019","unstructured":"Team RC (2019) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria"},{"issue":"1","key":"6608_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.21037\/atm.2016.08.57","volume":"5","author":"Z Zhang","year":"2017","unstructured":"Zhang Z (2017) Propensity score method: a non-parametric technique to reduce model dependence. Ann Transl Med. 5(1):7","journal-title":"Ann Transl Med."},{"issue":"13","key":"6608_CR17","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1177\/1352458516653667","volume":"22","author":"T Kalincik","year":"2016","unstructured":"Kalincik T, Butzkueven H (2016) Observational data: understanding the real MS world. Mult Scler. 22(13):1642\u20131648","journal-title":"Mult Scler."},{"issue":"5","key":"6608_CR18","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"JA Cohen","year":"2010","unstructured":"Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X et al (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 362(5):402\u2013415","journal-title":"N Engl J Med."},{"key":"6608_CR19","first-page":"Cd009371","volume":"4","author":"L La Mantia","year":"2016","unstructured":"La Mantia L, Tramacere I, Firwana B, Pacchetti I, Palumbo R, Filippini G (2016) Fingolimod for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev. 4:Cd009371","journal-title":"Cochrane Database Syst Rev."},{"issue":"10","key":"6608_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-038861","volume":"10","author":"H Butzkueven","year":"2020","unstructured":"Butzkueven H, Licata S, Jeffery D, Arnold DL, Filippi M, Geurts JJ et al (2020) Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study. BMJ Open. 10(10):e038861","journal-title":"BMJ Open."},{"issue":"Pt 11","key":"6608_CR21","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1093\/brain\/awv260","volume":"138","author":"P Iaffaldano","year":"2015","unstructured":"Iaffaldano P, Lucisano G, Pozzilli C, Brescia Morra V, Ghezzi A, Millefiorini E et al (2015) Fingolimod versus interferon beta\/glatiramer acetate after natalizumab suspension in multiple sclerosis. Brain. 138(Pt 11):3275\u20133286","journal-title":"Brain."},{"issue":"2","key":"6608_CR22","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/acn3.700","volume":"6","author":"BL Vollmer","year":"2019","unstructured":"Vollmer BL, Nair KV, Sillau S, Corboy JR, Vollmer T, Alvarez E (2019) Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment. Ann Clin Transl Neurol. 6(2):252\u2013262","journal-title":"Ann Clin Transl Neurol."},{"issue":"6","key":"6608_CR23","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/ana.24651","volume":"79","author":"P Alping","year":"2016","unstructured":"Alping P, Frisell T, Novakova L, Islam-Jakobsson P, Salzer J, Bj\u00f6rck A et al (2016) Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann Neurol. 79(6):950\u2013958","journal-title":"Ann Neurol."},{"issue":"8","key":"6608_CR24","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1111\/ene.13936","volume":"26","author":"M Boremalm","year":"2019","unstructured":"Boremalm M, Juto A, Axelsson M, Novakova L, Frisell T, Svenningsson A et al (2019) Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. Eur J Neurol. 26(8):1060\u20131067","journal-title":"Eur J Neurol."},{"issue":"3","key":"6608_CR25","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1001\/jamaneurol.2017.4011","volume":"75","author":"M Granqvist","year":"2018","unstructured":"Granqvist M, Boremalm M, Poorghobad A, Svenningsson A, Salzer J, Frisell T et al (2018) Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurol. 75(3):320\u2013327","journal-title":"JAMA Neurol."},{"issue":"12","key":"6608_CR26","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1007\/s00415-019-09395-w","volume":"267","author":"H Li","year":"2020","unstructured":"Li H, Hu F, Zhang Y, Li K (2020) Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis. J Neurol. 267(12):3489\u20133498","journal-title":"J Neurol."},{"key":"6608_CR27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.msard.2018.12.040","volume":"29","author":"R McCool","year":"2019","unstructured":"McCool R, Wilson K, Arber M, Fleetwood K, Toupin S, Thom H et al (2019) Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis. Mult Scler Relat Disord. 29:55\u201361","journal-title":"Mult Scler Relat Disord."},{"key":"6608_CR28","doi-asserted-by":"crossref","unstructured":"Bigaut K, Kremer L, Fabacher T, Ahle G, Goudot M, Fleury M et al (2022) Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study. J Neurol. 1-6","DOI":"10.1007\/s00415-021-10950-7"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-06608-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-023-06608-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-06608-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T03:48:54Z","timestamp":1683863334000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-023-06608-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,23]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["6608"],"URL":"https:\/\/doi.org\/10.1007\/s10072-023-06608-z","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,23]]},"assertion":[{"value":"26 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical committee approval was obtained from the Karadeniz Technical University Medical Faculty Ethical Committee. Each center received local regulation and local ethical committee approval for registry use for all multiple sclerosis (MS) patients. Written informed consent was required from all participating patients at each center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Cavit Boz received conference travel support from Biogen, Novartis, Bayer-Schering, Merck, and Teva, and has participated in clinical trials by Sanofi Aventis, Roche, and Novartis. Murat Terzi received travel grants from Novartis, Bayer-Schering, Merck, and Teva, and has participated in clinical trials by Sanofi Aventis, Roche, and Novartis. Serkan Ozakbas did not declare any competing interests. Rana Karabudak did not declare any competing interests related to this study. Serhan Sevim did not declare any competing interests. Recai Turkoglu did not declare any competing interests. Aysun Soysal did not declare any competing interests. Belgin Petek Balc\u0131 did not declare any competing interests. H\u00fcsn\u00fc Efendi did not declare any competing interests. \u00d6mer Faruk Turan did not declare any competing interests. Nur Y\u00fcceyar did not declare any competing interests. Mehmet Fatih Yetkin did not declare any competing interests. Serap Zengin Karahan did not declare any competing interests. Meltem Demirk\u0131ran did not declare any competing interests. Sibel Guler did not declare any competing interests. Kadriye Agan did not declare any competing interests. Nefati K\u0131yl\u0131o\u011flu received conference travel support from Novartis, Bayer-Schering, Merck, and Teva. Cavid Baba did not declare any competing interests. Asli Tuncer did not declare any competing interests. Mesrure K\u00f6seo\u011flu did not declare any competing interests. Recai Turkoglu did not declare any competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}